Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Total Liabilities (2016 - 2026)

Usana Health Sciences (USNA) has disclosed Total Liabilities for 16 consecutive years, with $145.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Total Liabilities rose 4.93% to $145.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $145.0 million, a 4.93% increase, with the full-year FY2024 number at $161.9 million, up 19.41% from a year prior.
  • Total Liabilities was $145.0 million for Q3 2025 at Usana Health Sciences, down from $203.5 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $216.8 million in Q1 2025 to a low of $119.2 million in Q2 2024.
  • A 5-year average of $161.2 million and a median of $158.1 million in 2022 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: fell 19.4% in 2022, then surged 70.68% in 2025.
  • Usana Health Sciences' Total Liabilities stood at $179.9 million in 2021, then dropped by 9.89% to $162.1 million in 2022, then fell by 16.36% to $135.6 million in 2023, then increased by 19.41% to $161.9 million in 2024, then fell by 10.39% to $145.0 million in 2025.
  • Per Business Quant, the three most recent readings for USNA's Total Liabilities are $145.0 million (Q3 2025), $203.5 million (Q2 2025), and $216.8 million (Q1 2025).